Bristol-Myers Squibb completes divestment of manufacturing facility in Anagni, ItalyChristian Fernsby ▼ | January 7, 2020
Bristol-Myers Squibb Company announced today that it has completed its previously announced divestment of its oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy, to Catalent Inc.
Acquisition Bristol-Myers Squibb
Topics: Bristol-Myers Squibb divest manufacturing facility Italy
The Anagni facility manufactures and packages cardiovascular, anticancer, metabolic and anti-inflammatory medicines as well as non-penicillin-based antibiotics, antivirals, analgesics as injectables and biologics. The Company is focusing resources on its highest priorities of discovering, developing and delivering transformational medicines for patients facing serious diseases. ■